Compare Novo Nordisk A/S (NVO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prudential Financial Inc — how do they compare? Novo Nordisk A/S trades at $44.71 (market cap $200.69B), while Prudential Financial Inc trades at $117.62 (market cap $41.19B). The key difference: Novo Nordisk A/S is far larger — about 4.9× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.69%). Which is the better fit depends on your goals.
| NVO | PRU | |
|---|---|---|
Market Cap | $200.69B | $41.19B |
Sector | Health | Financials |
52-Week High | $63.98 | $125.13 |
52-Week Low | $35.29 | $92.00 |
Enterprise Value | $215.49B | $69.96B |
Dividend Yield | 3.98% | 4.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
PRU trades at $119.38, down 2.16% today, with a neutral technical outlook and mixed earnings history. The stock shows strong profitability with a 6.04% net margin and 12.46% ROE, while valuation metrics like a P/E of 10.82 and P/S of 0.64 appear attractive. Recent news highlights PGIM's ETF launches and conference participation, signaling strategic focus.
The outlook is cautious; analyst consensus is a Hold with a $113.20 target below the current price. Risks include volatile cash flows and high leverage, but steady dividends and earnings beats offer support. Upside depends on execution of cost reductions and capital-light growth amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
